Multiple trials, thousands of participants, and consistent results across different populations
Conclusion This exit interview study provides qualitative evidence to support the interpretation of the clinical trial findings for retatrutide in the treatment of obesity, with detailed descriptions from participants of positive experiences relating to weight loss, eating behaviors, physical aspects, emotions, and lifestyle
If a licensed Nexa provider determines you're not eligible for GLP-1 therapy, you receive a full refund before anything ships
Over 52 weeks, resolution of MASH without worsening of fibrosis was achieved in 10% of the placebo group, 44% of the tirzepatide 5 mg group, 56% of the 10 mg group, and 62% of the 15 mg group